why choose us

First received: June 06, 2023

Clinical Trial: A Study of EXG102-031 in Patients With wAMD (Everest)

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Neovascular (Wet) Age-related Macular Degeneration (nAMD)

Study Type: INTERVENTIONAL


Official Title: An Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration.

Brief Summary: In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.This leakage affects the vision over time and can lead to severe blurriness or blinding.EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision.Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is…

Read more